Analystreport

Aileron Therap (NASDAQ: ALRN) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $19.00 price target on the stock.

Aileron Therapeutics, Inc.  (ALRN) 
Last aileron therapeutics, inc. earnings: 11/7 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investors.aileronrx.com